Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897

This publication has 42 references indexed in Scilit:

• Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies
  Annals of Internal Medicine, 2003
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
  Nature, 2002
• A Portrait of Alzheimer Secretases--New Features and Familiar Faces
  Science, 2001
• Regulation of APP cleavage by α‐, β‐ and γ‐secretases
  FEBS Letters, 2000
• Amyloid β Protein in Plasma as a Diagnostic Marker for Alzheimer’s Disease
  Neurobiology of Aging, 1998
• The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue
  Proceedings of the National Academy of Sciences, 1997
• Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
  Nature Medicine, 1996
• New Insights into the Genetics of Alzheimer's Disease
  Annals of Medicine, 1996
• The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
  Biochemistry, 1993
• Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
  Nature, 1992